Pyxis Oncology (PYXS) announced the appointment of Michael Metzger to its Board of Directors, effective June 10, 2024. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals (SNDX) since 2015.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYXS:
- Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
- Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
- Pyxis Oncology expects to have a cash runway to fund operations into 2H 2026
- Pyxis Oncology reports Q1 EPS (6c), consensus (25c)
- Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024